ESGCT 29th Annual Congress In collaboration with BSGCT Edinburgh, UK October 11–14, 2022 Abstracts

ABSTRACT

P700 A novel platform for engineered AAV-based vaccines S Babutzka SP 1 sp L Zobel SP 1 sp J Bogedein SP 1 sp M Diedrichs-Möhring SP 1 sp M Gehrke SP 1 sp G Wildner SP 1 sp H Ammer SP 2 sp S Michalakis SP 1 sp I 1 Department of Ophthalmology, University Hospital, LMU Munich, 80336 Munich, Germany 2 Department of Veterinary Sciences, Ludwig-Maximilians-Universität München, Munich, Germany i The still ongoing pandemic has highlighted the unmet need for more innovative and rapidly adaptable vaccine platforms. P702 Circumventing anti-vector immunity towards adenoviral vectored vaccines C M Bliss SP 1 sp J A Davies SP 1 sp M Marusková SP 1 sp L M Badder SP 1 sp M A Oliver SP 2 sp L Stack SP 1 sp A T Baker SP 1 sp A L Parker SP 1 sp I 1 Cardiff University 2 InBio i Replication deficient (RD) adenoviruses (Ad) are the most widely administered viral vectors, with licensed SARS-CoV-2 vaccines using vectors derived from human Ad type 5 (Ad5) and 26 (Ad26), and chimpanzee Ad " I ChAdOx1 i ". P704 Characterization of adenovirus interactions with PF4 using a novel ELISA-qPCR technology E Sallard SP 1 sp F Kreppel SP 1 sp A Ehrhardt SP 1 sp I 1 Witten/Herdecke University i The COVID vaccines Janssen and AstraZeneca, based respectively on adenovirus (AdV) serotypes AdV26 and ChAdOx1, have been associated with rare cases of vaccine-induced thrombotic thrombocytopenia (VITT). This next-generation vaccine platform based on AAV capsids with large insertions of immunogenic sequences enables strong and specific immune responses without the need for genomically encoded immunogens, thus reducing the risk of potentially pathogenic intracellular processes associated with viral vector genomes and prolonged transgene expression. [Extracted from the article]